HomeCompareCAVG vs ABBV

CAVG vs ABBV: Dividend Comparison 2026

CAVG yields 666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAVG wins by $608115.56M in total portfolio value
10 years
CAVG
CAVG
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full CAVG calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CAVG vs ABBV

📍 CAVG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAVGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAVG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAVG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAVG
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CAVG beats the other by $399,126,844,937.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAVG + ABBV for your $10,000?

CAVG: 50%ABBV: 50%
100% ABBV50/50100% CAVG
Portfolio after 10yr
$304057.88M
Annual income
$234,780,521,794.00/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CAVG
No analyst data
Altman Z
-115.9
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAVG buys
0
ABBV buys
0
No recent congressional trades found for CAVG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAVGABBV
Forward yield666.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$608115.66M$102.3K
Annual income after 10y$469,561,018,816.25$24,771.77
Total dividends collected$596792.85M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CAVG vs ABBV ($10,000, DRIP)

YearCAVG PortfolioCAVG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$77,367$66,666.67$11,550$430.00+$65.8KCAVG
2$564,818$482,035.31$13,472$627.96+$551.3KCAVG
3$3,893,246$3,288,890.67$15,906$926.08+$3.88MCAVG
4$25,352,760$21,186,987.16$19,071$1,382.55+$25.33MCAVG
5$156,070,781$128,943,327.59$23,302$2,095.81+$156.05MCAVG
6$908,837,800$741,842,064.29$29,150$3,237.93+$908.81MCAVG
7$5,009,769,782$4,037,313,336.56$37,536$5,121.41+$5009.73MCAVG
8$26,159,339,258$20,798,885,591.56$50,079$8,338.38+$26159.29MCAVG
9$129,490,317,125$101,499,824,118.87$69,753$14,065.80+$129490.25MCAVG
10$608,115,658,140$469,561,018,816.25$102,337$24,771.77+$608115.56MCAVG

CAVG vs ABBV: Complete Analysis 2026

CAVGStock

ACC Aviation Holdings Ltd. focuses on developing canna powder products. Its canna powder is a nano-powder derived from cannabis oil. The company was formerly known as Elfato Inc. The company was founded in 1999 and is based in Los Angeles, California.

Full CAVG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CAVG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAVG vs SCHDCAVG vs JEPICAVG vs OCAVG vs KOCAVG vs MAINCAVG vs JNJCAVG vs MRKCAVG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.